Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
SASage Therapeutics, Inc. logo

Sage Therapeutics, Inc. (SAGE)

NASDAQ Global Market · Currency in USD
$8.68 ▲ +0.00 (+0.00%)
At close: Jul 31, 4:00 PM ET. Market closed.

Summary

Previous Close
$8.68
Open
$8.68
Day's Range
$8.68 – $8.68
52 Week Range
$4.62 – $9.36
Volume
17,394,354
Avg. Volume
2,480,352
Market Cap
$544.94M
Beta (5Y Monthly)
0.30
PE Ratio (TTM)
--
EPS (TTM)
-$6.59
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$37.33

Profile: Sage Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
353
CEO
Barry E. Greene

Sage Therapeutics, Inc. functions as a biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of therapeutic agents aimed at central nervous system (CNS) conditions. Its primary medication is ZULRESSO, an intravenous form of brexanolone, prescribed for the treatment of postpartum depression (PPD) in adult patients. The company's advanced pipeline includes zuranolone, a neuroactive steroid, which is presently undergoing Phase III clinical trials for several disorders, such as PPD, major depressive disorders, treatment-resistant depression, generalized anxiety disorders, and bipolar depression.

Earnings

DateEst.Actual
Jul 30, 2025-$0.96-$0.79Beat
Apr 29, 2025-$0.99-$1.01Miss
Feb 11, 2025-$1.54-$1.56Miss
Oct 29, 2024-$1.52-$1.53Miss
Jul 31, 2024-$1.68-$1.70Miss
Apr 25, 2024-$1.63-$1.80Miss

Analyst view

Consensus price target
$37.33 ▲ +330.1%
Range $5.00 – $105.00
Rating: Hold
Buy 19% · Hold 75% · Sell 6%

Get free alerts on SAGE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.